PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, DNA encoded library technology, and mega virtual lib… Read more
PharmaBlock Sciences Nanjing Inc Class A (300725) - Total Assets
Latest total assets as of September 2025: CN¥7.79 Billion CNY
Based on the latest financial reports, PharmaBlock Sciences Nanjing Inc Class A (300725) holds total assets worth CN¥7.79 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
PharmaBlock Sciences Nanjing Inc Class A - Total Assets Trend (2013–2024)
This chart illustrates how PharmaBlock Sciences Nanjing Inc Class A’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
PharmaBlock Sciences Nanjing Inc Class A - Asset Composition Analysis
Current Asset Composition (December 2024)
PharmaBlock Sciences Nanjing Inc Class A's total assets of CN¥7.79 Billion consist of 55.1% current assets and 45.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 5.9% |
| Accounts Receivable | CN¥485.61 Million | 9.8% |
| Inventory | CN¥840.17 Million | 17.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥107.98 Million | 2.2% |
| Goodwill | CN¥355.74 Million | 7.2% |
Asset Composition Trend (2013–2024)
This chart illustrates how PharmaBlock Sciences Nanjing Inc Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PharmaBlock Sciences Nanjing Inc Class A's current assets represent 55.1% of total assets in 2024, a decrease from 65.7% in 2013.
- Cash Position: Cash and equivalents constituted 5.9% of total assets in 2024, down from 22.8% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 2.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 17.0% of total assets.
PharmaBlock Sciences Nanjing Inc Class A Competitors by Total Assets
Key competitors of PharmaBlock Sciences Nanjing Inc Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
PharmaBlock Sciences Nanjing Inc Class A - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - PharmaBlock Sciences Nanjing Inc Class A generates 0.34x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, PharmaBlock Sciences Nanjing Inc Class A generates $ 4.45 in net profit.
PharmaBlock Sciences Nanjing Inc Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.59 | 3.33 | 3.94 |
| Quick Ratio | 3.43 | 2.21 | 3.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.08 Billion | CN¥ 1.88 Billion | CN¥ 1.40 Billion |
PharmaBlock Sciences Nanjing Inc Class A - Advanced Valuation Insights
This section examines the relationship between PharmaBlock Sciences Nanjing Inc Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.33 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | -3.3% |
| Total Assets | CN¥4.94 Billion |
| Market Capitalization | $788.29 Million USD |
Valuation Analysis
Below Book Valuation: The market values PharmaBlock Sciences Nanjing Inc Class A's assets below their book value (0.16 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: PharmaBlock Sciences Nanjing Inc Class A's assets decreased by 3.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for PharmaBlock Sciences Nanjing Inc Class A (2013–2024)
The table below shows the annual total assets of PharmaBlock Sciences Nanjing Inc Class A from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.94 Billion | -3.31% |
| 2023-12-31 | CN¥5.10 Billion | +4.97% |
| 2022-12-31 | CN¥4.86 Billion | +38.65% |
| 2021-12-31 | CN¥3.51 Billion | +44.60% |
| 2020-12-31 | CN¥2.43 Billion | +135.66% |
| 2019-12-31 | CN¥1.03 Billion | +35.21% |
| 2018-12-31 | CN¥761.16 Million | +34.15% |
| 2017-12-31 | CN¥567.40 Million | +89.67% |
| 2016-12-31 | CN¥299.15 Million | +73.44% |
| 2015-12-31 | CN¥172.48 Million | +69.83% |
| 2014-12-31 | CN¥101.56 Million | +19.30% |
| 2013-12-31 | CN¥85.13 Million | -- |